首页> 外文期刊>International Journal of Research in Medical Sciences >A comparative study on efficacy of metoprolol and ivabradine in acute ST elevation myocardial infarction patients
【24h】

A comparative study on efficacy of metoprolol and ivabradine in acute ST elevation myocardial infarction patients

机译:美托洛尔和伊伐布雷定在急性ST段抬高型心肌梗死患者中的疗效比较研究

获取原文
           

摘要

Background: The ST-elevation myocardial infarction (STEMI), a fatal disease, is rapidly extending in patients, worldwide. Therefore, proper and timely diagnosis followed by appropriate management becomes necessary. The study aimed to compare the effectiveness of metoprolol and ivabradine in acute STEMI patients. Methods: This was an observational, comparative, in-hospital study carried out in patients admitted in the in-patient cardiac department, intensive cardiac care unit of a tertiary care centre in India. Total 60 patients diagnosed with acute ST-elevation MI were included in the study and were equally divided into two groups. Group 1 involved patients who were given metoprolol for treatment and group 2 involved patients who were given ivabradine. The patients were assessed in terms of heart rate, NYHA class, and ejection fraction. Follow-up of 30 days was taken in all patients. Results: Ivabradine reduced mean heart rate from 85.57 bpm at baseline to 78.23 bpm. Heart rate in the metoprolol group was reduced from 81.93 bpm to 76.47 bpm over the same time period. Metoprolol and ivabradine showed significant improvement in the ejection fraction volume during the in-hospitalization stay. Ivabradine showed a better improvement in ejection fraction when compared to metoprolol but the difference was not found to be statistically significant. Higher mortality was assessed in ivabradine group compared to metoprolol. Conclusions: The study gives the gold standard efficacy and mortality benefit of metoprolol, although ivabradine on the other hand gave better responses in heart rate reduction and improvements in ejection fraction.
机译:背景:ST抬高型心肌梗死(STEMI)是一种致命疾病,在世界范围内的患者中迅速蔓延。因此,必须进行适当,及时的诊断,然后进行适当的管理。该研究旨在比较美托洛尔和伊伐布雷定在急性STEMI患者中的有效性。方法:这是一项对印度三级护理中心重症监护病房住院心脏科住院的患者进行的观察性,对比性住院研究。研究共纳入60例诊断为急性ST抬高型MI的患者,并将其平均分为两组。第一组涉及接受美托洛尔治疗的患者,第二组涉及接受伊伐布雷定的患者。根据心律,NYHA分级和射血分数对患者进行评估。所有患者均接受了30天的随访。结果:伊伐布雷定将平均心率从基线的85.57 bpm降低到78.23 bpm。在同一时期,美托洛尔组的心率从81.93 bpm降低到76.47 bpm。美托洛尔和伊伐布雷定在住院期间表现出射血分数明显改善。与美托洛尔相比,伊伐布雷定显示出射血分数更好的改善,但差异无统计学意义。与美托洛尔相比,伊伐布雷定组的死亡率更高。结论:尽管伊伐布雷定在降低心率和改善射血分数方面具有更好的反应,但该研究给出了美托洛尔的金标准疗效和死亡率益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号